AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support

Rhea-AI Summary

AbbVie (NYSE: ABBV) announced that 34 students living with inflammatory conditions will receive the 2026 AbbVie Immunology Scholarship, coinciding with the program’s 10th year. Since 2016, AbbVie has provided more than $6 million in scholarships, supporting over 350 U.S. students pursuing higher education.

According to AbbVie, the scholarship is now a renewable award of up to $20,000 per student, which recipients may renew for up to three additional years. The 2026 class includes 3 new recipients and 31 renewing their awards. The program supports students managing conditions such as atopic dermatitis, psoriasis, Crohn's disease, ulcerative colitis and juvenile idiopathic arthritis, and selection is based on academic achievement, leadership, community involvement, essays and recommendations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Since its 2016 launch, hundreds of exceptional students pursuing higher education have received the scholarship
• Now a renewable award, students may earn the AbbVie Immunology Scholarship for up to four years
• Recipients live with conditions such as atopic dermatitis, psoriasis, Crohn's disease, ulcerative colitis and juvenile idiopathic arthritis

NORTH CHICAGO, Ill., Aug. 18, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced 34 students living with inflammatory conditions across dermatology, gastroenterology and rheumatology will receive the 2026 AbbVie Immunology Scholarship, as the program marks its 10^th year.

During the past decade, AbbVie has invested more than $6 million through the scholarship, helping more than 350 students across the U.S. pursue higher education.

Renewable awards increase impact
Last year, the scholarship evolved to offer larger, renewable awards of up to $20,000 per student. Once selected, recipients may renew their scholarship for up to three additional years.

As college tuition has risen nearly 37% since 2010,¹ research shows college students with chronic illnesses may experience unique financial barriers² and are at significant risk for health problems, educational disruptions and lower graduation rates.³ The AbbVie Immunology Scholarship provides sustained support as recipients work toward their educational goals while managing their health.   

"With the demands of coursework, medical care and the cost of higher education, living with an immune-mediated disease can add significant challenges to a student's academic experience," said Jag Dosanjh, senior vice president of AbbVie and president of Immunology at AbbVie. "As we celebrate the 10th anniversary of the AbbVie Immunology Scholarship, we're proud to recognize our recipients' resilience and academic excellence and help them fulfill their educational and professional aspirations."

Making a difference for postsecondary students
The 2026 class includes three new recipients and 31 renewing their scholarships.

"I am proud to stand among fellow recipients whose character, determination and accomplishments continue to inspire me," said Alessandro Ruiz, who is receiving the AbbVie Immunology Scholarship for a second year, as he works toward a bachelor's degree in business analytics and operations and supply chain management at the University of North Carolina at Charlotte. "This award will significantly support my pursuit of ambitious academic goals and provide meaningful acknowledgment of the perseverance that has shaped my journey."  

The AbbVie Immunology Scholarship recognizes outstanding students pursuing associate, bachelor's, master's and doctoral degrees, while living with an inflammatory disease. Recipients are chosen based on academic achievement, leadership, community involvement, essay submissions and recommendation letters.

To learn more about the scholarship and this year's recipients, visit www.AbbVieImmunologyScholarship.com.

About the AbbVie Immunology Scholarship
The AbbVie Immunology Scholarship provides financial support to exceptional students living with chronic inflammatory diseases who are pursuing higher education in the United States. Through this scholarship, AbbVie's passion for patient care extends beyond medicine by helping students pursue a degree—and a life—not defined by their disease. Scholarship applicants are not required to have taken, currently take or intend to take any medicine or product marketed by AbbVie, and treatment history is not considered during the selection process. Recipients may renew their scholarship for up to three additional years or until they earn a bachelor's or graduate degree, whichever occurs first, provided they continue to meet eligibility requirements.

About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For more than 20 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.

Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 19 immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements 
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

U.S Media: Karen May karen.may@abbvie.com

Investors: Liz Shea liz.shea@abbvie.com

¹ Hanson, M. "College Tuition Inflation Rate." Education Data Initiative. https://educationdata.org/college-tuition-inflation-rate. Last updated Nov. 26, 2025.  
² Issacson, K. and Tuckwiller, E. (2025) "Students with Chronic Illnesses Navigating the College Transition: Evidence from One Four-Year U.S. University." Journal of Postsecondary Education and Disability. https://files.eric.ed.gov/fulltext/EJ1483220.pdf.   
³ Lemly, D. et al. (2014) "College Health Service Capacity to Support Youth with Chronic Medical Conditions." Pediatrics. 2014 Nov;134(5):885–891. doi: 10.1542/peds.2014-1304.   

View original content:https://www.prnewswire.com/news-releases/abbvie-announces-2026-abbvie-immunology-scholarship-recipients-celebrating-10-years-of-support-302853354.html

SOURCE AbbVie

FAQ

What is the AbbVie (ABBV) Immunology Scholarship announced for 2026?

The 2026 AbbVie Immunology Scholarship is a financial aid program supporting 34 U.S. students living with inflammatory diseases. According to AbbVie, it recognizes academic achievement, leadership and community involvement among students pursuing associate, bachelor’s, master’s or doctoral degrees while managing chronic inflammatory conditions.

How much funding does the 2026 AbbVie (ABBV) Immunology Scholarship provide per student?

The AbbVie Immunology Scholarship now offers awards of up to $20,000 per student. According to AbbVie, these larger awards are intended to address rising tuition costs and financial barriers faced by college students with chronic illnesses pursuing degrees at accredited U.S. institutions.

Is the AbbVie (ABBV) Immunology Scholarship renewable, and for how long?

Yes, the AbbVie Immunology Scholarship is renewable for up to three additional years. According to AbbVie, recipients may receive support for as many as four years total, or until they complete a bachelor’s or graduate degree, provided they continue meeting eligibility requirements.

How many students have benefited from the AbbVie (ABBV) Immunology Scholarship over 10 years?

Over the past decade, more than 350 students have received support through the AbbVie Immunology Scholarship. According to AbbVie, the company has invested over $6 million since 2016 to help U.S. students with inflammatory diseases pursue higher education goals.

Do applicants need to use AbbVie medicines to qualify for the AbbVie (ABBV) Immunology Scholarship?

No, using AbbVie medicines is not required to qualify for the scholarship. According to AbbVie, applicants do not need to have taken, currently take, or intend to take any AbbVie product, and treatment history is not considered in the selection process.

What conditions are represented among 2026 AbbVie (ABBV) Immunology Scholarship recipients?

Recipients live with chronic inflammatory conditions, including atopic dermatitis, psoriasis, Crohn's disease, ulcerative colitis and juvenile idiopathic arthritis. According to AbbVie, the scholarship focuses on students managing immune-mediated diseases in dermatology, gastroenterology and rheumatology while pursuing higher education.

How many new and returning scholars are in the 2026 AbbVie (ABBV) Immunology Scholarship class?

The 2026 class includes 3 new scholarship recipients and 31 renewing their awards. According to AbbVie, this structure reflects the program’s renewable design, allowing previously selected students to continue receiving support if they maintain eligibility.